Antioxidant
Conditions
Interventions
The present study is a double-blind, placebo-controlled randomized clinical trial for the treatment variable with Ribose Cysteine, consisting of three groups, namely: intervention group I, where 20 he
intervention group II, where 20 healthy individuals aged between 40 and 59 years, will receive the cysteine ribose formulation nº 2, will consume 2 capsules twice a day for 30 days, equivalent to 250
D09.947.875.627.651
D02.886.030.230
D26.660
Sponsors
Universidade do Sul de Santa Catarina
Universidade do Sul de Santa Catarina
Eligibility
Age
40 Years to 59 Years
Inclusion criteria
Inclusion criteria: Healthy individuals; of both sexes; between the ages of 40 and 59 years
Exclusion criteria
Exclusion criteria: Individuals who use supplements to increase mitochondrial activity; nitric oxide; antioxidants or to reduce inflammation; and who have injuries that may make participation in the study difficult
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that individuals who will receive supplementation with Ribose Cysteine will show a significant decrease in the oxidative stress marker (malondialdehyde) and an increase in the antioxidant enzyme (glutathione) | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected that individuals supplemented with Ribose Cysteine will have lower scores obtained on the Fatigue Assessment Scale than the scores prior to the start of treatment;It is expected that individuals supplemented with Ribose Cysteine will have a lower score on the Perceived Stress Scale than the scores prior to the start of treatment;It is expected that individuals supplemented with Cysteine Ribose will have better sleep quality reported through the Pittsburgh Quality of Sleep Index (PSQI-BR) tool, showing a reduction in the score after supplementation;It is expected that individuals supplemented with Cysteine Ribose have demonstrated improvement in the Oxidative Stress Assessment tool, identifying themselves with fewer stressors;The effects of Cysteine Ribose in healthy individuals will be evaluated, on serum levels of: Citrate synthase; Malondialdehyde (MDA); Total glutathione levels; High sensitivity C-reactive protein (hs-CRP) | — |
Countries
Brazil
Contacts
Public ContactBruna Fernandes
Universidade do Sul de Santa Catarina
Outcome results
None listed